Cited by 38Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsNeurobiology and Insect Physiology Research

Integrated biology approach reveals molecular and pathological interactions among Alzheimer’s Aβ42, Tau, TREM2, and TYROBP in Drosophila models

Open access
Sekiya, Michiko, Wang, Minghui, Fujisaki, Naoki, Sakakibara, Yasufumi, Quan, Xiuming, Ehrlich, Michelle E., De Jager, Philip L., Bennett, David A. +5 more·2018·Genome Medicine

Abstract

BACKGROUND: Cerebral amyloidosis, neuroinflammation, and tauopathy are key features of Alzheimer's disease (AD), but interactions among these features remain poorly understood. Our previous multiscale molecular network models of AD revealed TYROBP as a key driver of an immune- and microglia-specific network that was robustly associated with AD pathophysiology. Recent genetic studies of AD further identified pathogenic mutations in both TREM2 and TYROBP. METHODS: In this study, we systematically examined molecular and pathological interactions among Aβ, tau, TREM2, and TYROBP by integrating signatures from transgenic Drosophila models of AD and transcriptome-wide gene co-expression networks from two human AD cohorts. RESULTS: Glial expression of TREM2/TYROBP exacerbated tau-mediated neurodegeneration and synergistically affected pathways underlying late-onset AD pathology, while neuronal Aβ42 and glial TREM2/TYROBP synergistically altered expression of the genes in synaptic function and immune modules in AD. CONCLUSIONS: The comprehensive pathological and molecular data generated through this study strongly validate the causal role of TREM2/TYROBP in driving molecular networks in AD and AD-related phenotypes in flies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13073-018-0530-9

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Up to one-third of patients with a clinical diagnosis of AD have no accumulation of Aβ.

    “For instance, up to one-third of patients with a clinical diagnosis of AD have no accumulation of Aβ (4)”

    From Molecular subtyping of Alzheimer’s disease using RNA sequencing data reveals novel mechanisms and targets (2021) · cites this paper as [4]

    The Background states that up to one-third of patients with clinically diagnosed AD have no evidence of amyloidosis on brain amyloid imaging. That supports the proportion and clinical-diagnosis qualifier, but an imaging result does not establish that they have no Aβ accumulation at all. No page number is provided in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • AD is a heterogeneous disease caused by various pathophysiologic mechanisms beyond the typical dogma.

    “However, an increasingly growing body of evidence has demonstrated that AD is a heterogeneous disease caused by various pathophysiologic mechanisms beyond the typical dogma.”
  • Cognitive impairment is neither dependent on nor fully assured by high levels of Aβ and tau accumulation.

    “These findings are consistent with previous studies that have shown that cognitive impairment is neither dependent on nor fully assured by high levels of Aβ and tau accumulation (4, 5).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sekiya, M., Wang, M., Fujisaki, N., Sakakibara, Y., Quan, X., Ehrlich, M. E., De Jager, P. L., Bennett, D. A., Schadt, E. E., Gandy, S., Ando, K., Zhang, B., & Iijima, K. M.
Affiliations
  • National Center for Geriatrics and Gerontology (JP)
  • Icahn School of Medicine at Mount Sinai (US)
  • Nagoya City University (JP)
  • Rush University Medical Center (US)
  • James J. Peters VA Medical Center (US)
  • Tokyo Metropolitan University (JP)
Corresponding author
  • Zhang, Bin
  • Iijima, Koichi M.
Venue
Genome Medicine
Published
2018-03-29
Volume
10
Issue
1
Pages
26-26
ISSN
1756-994X (ISSN-L)
OpenAlex
W2795614235
Cited by
38
References
82
Citations by year
2026: 3 · 2025: 5 · 2024: 9 · 2023: 5 · 2022: 4 · 2021: 4 · 2020: 6 · 2019: 1 · 2018: 1
FWCI
2.05
Type
journal article
Language
en
Open access
Locations
  • Genome Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute on Aging (U01AG046170, U01AG46152, P30AG10161, RF1AG15819, R01AG36836, RF1AG054014, RF1AG057440, R01AG057907, U01AG052411)
  • National Center for Geriatrics and Gerontology (28-26)
  • Takeda Science Foundation
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurobiology and Insect Physiology Research
Keywords
Alzheimer's disease, amyloid-beta 42, tau protein, TREM2, TYROBP, microglia, neuroinflammation, cerebral amyloidosis, tauopathy, Drosophila model, gene co-expression network, synaptic function, neurodegeneration, glial gene expression
MeSH terms
Alzheimer Disease, Animals, Brain, Disease Models, Animal, Drosophila melanogaster, Female, Gene Expression Regulation, Humans, Male, Membrane Glycoproteins, Membrane Proteins, Nerve Degeneration, Neuroglia, Neurons, Receptors, Immunologic, Synapses, Signal Transduction, Amyloid beta-Peptides, tau Proteins, Drosophila Proteins, Animals, Genetically Modified, Adaptor Proteins, Signal Transducing, Gene Regulatory Networks

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review